Peptide Glossary
Quick answer: Peptide marketing uses technical terms that can sound more conclusive than they are. This glossary explains common language without turning a laboratory specification into a medical recommendation.
- Amino acid
- A building block used to form peptides and proteins.
- Assay
- A measurement intended to estimate how much target material is present.
- Certificate of analysis (COA)
- A document reporting selected test methods and results for a sample or batch.
- Compounded drug
- A preparation made under specific federal and state conditions for a patient or through an outsourcing facility. It is not FDA-approved.
- Counter-ion
- An ion associated with a peptide salt, which can affect molecular weight and formulation calculations.
- Half-life
- The time for a measured concentration to decrease by half under defined conditions. It does not by itself dictate a safe dosing schedule.
- HPLC
- High-performance liquid chromatography, commonly used to separate components and estimate chromatographic purity.
- Investigational
- Being studied and not yet approved for routine marketing for that use.
- Lyophilized
- Freeze-dried. The term describes a physical form, not sterility or quality.
- Mass spectrometry
- An analytical technique that can support identity testing based on mass-to-charge measurements.
- Purity
- A method-dependent estimate of target material relative to detected related substances.
- Research use only
- A label indicating laboratory intent; it does not establish human safety or suitability.
- Sterility
- Absence of viable microorganisms under the conditions of a validated test.
How to use this glossary
Technical terms should narrow a claim, not make it sound more authoritative. When a seller uses one of these words, ask for the method, specification, and product context behind it.
- Aggregation
- Association of peptide molecules into larger structures that can affect activity, stability, and immune response.
- Bioavailability
- The extent and rate at which active material reaches systemic circulation; it depends on route and formulation.
- Counter-ion
- An oppositely charged ion associated with a peptide salt, potentially affecting molecular-weight and content calculations.
- Endotoxin
- Components from certain bacteria that can cause significant reactions even when viable bacteria are absent.
- Immunogenicity
- The potential to trigger an immune response, which can be influenced by sequence, aggregation, impurities, route, and patient factors.
- Pharmacodynamics
- What a drug does to the body, including biological effects and dose-response relationships.
- Pharmacokinetics
- How the body absorbs, distributes, metabolizes, and eliminates a substance.
- Surrogate endpoint
- A measured marker used as a substitute for a direct clinical outcome.
- Adverse event
- An unfavorable medical occurrence after exposure; it does not automatically prove causation.
- Assay validation
- Evidence that a method is suitable for its intended purpose, including accuracy, precision, specificity, and range.
- Bioequivalence
- A regulatory comparison used for certain approved generic products; it is not established by matching ingredient names.
- Excipient
- An inactive formulation component that can influence stability, delivery, and tolerability.
- Investigational new drug
- A drug studied under an FDA-authorized research framework; investigational does not mean approved.
- Specification
- A predefined acceptance criterion for a material or product test.
Terms that require follow-up
\u201cPharmaceutical grade,\u201d \u201cclinical grade,\u201d \u201cGMP,\u201d \u201ctested,\u201d and \u201cbioidentical\u201d can be vague without a defined standard and evidence. Ask what each term means for the exact product.